Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
103 hedge funds and large institutions have $87.5M invested in Sanofi Contingent Value Rights in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 10 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% more capital invested
Capital invested by funds: $80.8M → $87.5M (+$6.65M)
1% less funds holding
Funds holding: 104 → 103 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$997K |
| 2 |
SCM
Stonehill Capital Management
New York
|
+$243K |
| 3 |
BHMP
Bardin Hill Management Partners
New York
|
+$74.8K |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$16.9K |
| 5 |
Goldman Sachs
New York
|
+$9.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
-$335K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$154K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$70K |
| 4 |
TL
TowerView LLC
New York
|
-$56.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55K |
GCVRZ Hedge Fund Activity: Q3 2019 in Review
103 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2019, worth a combined $87.5M — up 8.2% from $80.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GCVRZ and 9 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 11 added.
The largest buyer was Jet Capital Investors, adding an estimated $997K. The largest seller was DLD Asset Management, exiting entirely with an estimated $335K sold.
- 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2019, down from 104 in Q2 2019.
- Funds reported $87.5M of Sanofi Contingent Value Rights stock for Q3 2019, up 8.2% quarter-over-quarter.
- 9 funds opened new Sanofi Contingent Value Rights positions in Q3 2019 and 10 closed out, a net change of -1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q3 2019 was Jet Capital Investors, an estimated $997K added.
- The largest Sanofi Contingent Value Rights seller in Q3 2019 was DLD Asset Management, an estimated $335K sold.
Based on aggregated 13F filings for Q3 2019.